那兰度司他(nerandomilast)对肺纤维化患者生存的影响
基于FIBRONEER-IPF和FIBRONEER-ILD两项安慰剂对照试验的汇总数据,在平均16.7个月随访期内,那兰度司他9 mg bid和18 mg bid分别使死亡风险较安慰剂降低33%(HR 0.67,95%CI 0.49–0.90,p=0.009)和43%(HR 0.57,95%CI 0.41–0.78,p<0.001)。敏感性分析、 tipping point分析和暴露-反应分析均支持该生存获益,结论支持使用那兰度司他18 mg bid改善IPF和PPF患者的生存。
要点
- 那兰度司他18 mg bid使IPF和PPF患者死亡风险较安慰剂降低43%(HR 0.57,95%CI 0.41–0.78)。
- 那兰度司他9 mg bid使死亡风险降低33%(HR 0.67,95%CI 0.49–0.90,p=0.009)。
- 暴露-反应分析显示那兰度司他血浆暴露越高,死亡风险越低。
核心结论
- 那兰度司他可改善IPF和PPF患者的生存,支持使用18 mg bid。
研究设计与样本
- 基于FIBRONEER-IPF和FIBRONEER-ILD两项安慰剂对照试验的汇总数据进行分析。
- 主要分析采用Cox比例风险模型,基于除肺移植后死亡以外的所有死亡评估至死亡时间。
- 进行了协变量敏感性分析、tipping point分析、治疗期间及治疗后短期死亡补充分析和间发事件影响分析。
- 按那兰度司他暴露(稳态谷浓度)评估至死亡时间。
主要发现
- 汇总数据整个随访期(平均16.7个月)内,那兰度司他9 mg bid组较安慰剂死亡风险降低33%(HR 0.67,95%CI 0.49–0.90,p=0.009)。
- 那兰度司他18 mg bid组较安慰剂死亡风险降低43%(HR 0.57,95%CI 0.41–0.78,p<0.001)。
- 敏感性分析和补充分析与主要至死亡时间分析结果一致。
- Tipping point分析表明那兰度司他对死亡率的获益极不可能由缺失数据导致。
- 暴露-反应分析表明那兰度司他血浆暴露越高,死亡风险越低。
临床怎么用
- 对于IPF和PPF患者,可考虑使用那兰度司他18 mg bid以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the placebo-controlled FIBRONEER-IPF and FIBRONEER-ILD trials in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), the key secondary endpoint was not met but numerical benefits of nerandomilast on time to death (a secondary endpoint) were observed. We further investigated the robustness of the effect of nerandomilast on survival. METHODS: In both trials, the primary analysis of time to death was based on all deaths except those after lung transplant, using a Cox proportional hazards model. We performed sensitivity analyses of the impact of covariates, tipping point analyses, and supplementary analyses of deaths during and shortly after treatment and the impact of intercurrent events. We assessed time to death by exposure to nerandomilast (trough concentration at steady state). RESULTS: Based on pooled data from both trials, over the whole follow-up period (mean:16.7 months), the risk of death versus placebo was reduced by 33% (hazard ratio: 0.67 [95% CI: 0.49, 0.90]; p=0.009) with nerandomilast 9 mg bid and by 43% (hazard ratio: 0.57 [95% CI: 0.41, 0.78]; p<0.001) with nerandomilast 18 mg bid. Sensitivity analyses and supplementary analyses were consistent with the primary analysis of time to death. Tipping point analyses demonstrated a very low likelihood that the benefit of nerandomilast on mortality was due to missing data. Exposure-response analyses indicated that a higher plasma exposure to nerandomilast was associated with a lower risk of death. CONCLUSION: These analyses support the use of nerandomilast 18 mg bid to improve survival in patients with IPF and PPF.
引用
- Oldham JM, Assassi S, Azuma A, et al. Effect of nerandomilast on survival in patients with pulmonary fibrosis. Eur Respir J. 2026. PMID: 42532543. doi:10.1183/13993003.00338-2026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。